Etsuko Okada Selected Research

Etsuko Okada Research Topics

Disease

7	Neoplasms (Cancer) 06/2021 - 07/2006
7	Drug Eruptions (Drug Eruption) 01/2021 - 02/2017
5	Melanoma (Melanoma, Malignant) 02/2022 - 12/2018
2	Fibrosis (Cirrhosis) 09/2014 - 04/2011
2	Nephrogenic Fibrosing Dermopathy 09/2014 - 04/2011
2	Liver Diseases (Liver Disease) 01/2012 - 03/2008
1	Colitis 02/2022
1	Diarrhea 02/2022
1	Hidradenitis Suppurativa 01/2022
1	Lymphatic Metastasis 06/2021
1	Extramammary Paget Disease (Paget Disease, Extramammary) 06/2021
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 05/2021
1	Bullous Pemphigoid (Pemphigoid) 07/2020
1	Experimental Melanoma 01/2020
1	Exfoliative Dermatitis (Erythroderma) 08/2018
1	Cheilitis 02/2018
1	Inflammation (Inflammations) 01/2018
1	Mycosis Fungoides 01/2018
1	Psoriasis (Pustulosis Palmaris et Plantaris) 01/2018
1	Atrioventricular Block 06/2017
1	Hypopituitarism (Sheehan's Syndrome) 06/2017
1	Hypothyroidism 06/2017
1	Marginal Zone B-Cell Lymphoma (MALT Lymphoma) 04/2015
1	Anetoderma 04/2015
1	Dermatofibrosarcoma 08/2012
1	Kounis Syndrome 01/2012
1	Pulmonary Hypertension 01/2012
1	digital ulcers 01/2012
1	Systemic Scleroderma (Systemic Sclerosis) 01/2012
1	Gangrene 01/2012
1	Relative Energy Deficiency in Sport 04/2011
1	Mixed Connective Tissue Disease (MCTD) 03/2008
1	Ulcer 08/2007
1	Eccrine Porocarcinoma 08/2007
1	Lymphadenopathy 07/2006

Drug/Important Bio-Agent (IBA)

3	NivolumabIBA 02/2022 - 06/2017
3	secukinumabIBA 08/2018 - 02/2017
2	Immune Checkpoint InhibitorsIBA 02/2022 - 01/2020
2	Adalimumab (Humira)FDA Link 01/2022 - 02/2017
2	Cell Adhesion Molecule-1IBA 05/2021 - 01/2018
2	AntigensIBA 02/2021 - 01/2020
2	Peptides (Polypeptides)IBA 02/2021 - 01/2020
2	Bosentan (Tracleer)FDA Link 01/2012 - 03/2008
1	Infliximab (Remicade)FDA Link 02/2022
1	Prednisolone (Predate)FDA LinkGeneric 02/2022
1	IpilimumabIBA 02/2022
1	Methylprednisolone FDA LinkGeneric 02/2022
1	vedolizumabIBA 02/2022
1	dermcidinIBA 06/2021
1	Biomarkers (Surrogate Marker)IBA 06/2021
1	Antimicrobial PeptidesIBA 06/2021
1	Cell Adhesion MoleculesIBA 05/2021
1	Immunoglobulins (Immunoglobulin)IBA 05/2021
1	EpitopesIBA 02/2021
1	CytokinesIBA 02/2021
1	telaprevirIBA 01/2021
1	Small Interfering RNA (siRNA)IBA 11/2020
1	KalininIBA 07/2020
1	AutoantibodiesIBA 07/2020
1	OX40 LigandIBA 01/2020
1	OvalbuminIBA 01/2020
1	MicroRNAs (MicroRNA)IBA 01/2020
1	Androgen Receptors (Androgen Receptor)IBA 05/2018
1	enzalutamideIBA 05/2018
1	Pharmaceutical PreparationsIBA 05/2018
1	Imiquimod (Aldara)FDA LinkGeneric 01/2018
1	Interleukin-23 (Interleukin 23)IBA 01/2018
1	garenoxacinIBA 11/2017
1	Mesylates (Mesylate)IBA 11/2017
1	Memantine (Namenda)FDA Link 07/2017
1	Piperacillin FDA LinkGeneric 02/2017
1	Tazobactam FDA LinkGeneric 02/2017
1	S100 Proteins (S 100 Protein)IBA 12/2015
1	Fibronectins (Fibronectin)IBA 12/2015
1	Proteins (Proteins, Gene)FDA Link 12/2015
1	Proto-Oncogene Proteins c-sis (Platelet Derived Growth Factor B)IBA 12/2015
1	Factor XIIIaIBA 12/2015
1	NestinIBA 12/2015
1	Matrix Metalloproteinases (MMPs)IBA 04/2015
1	Endothelin-1 (Endothelin 1)IBA 09/2014
1	Endothelin Receptors (Endothelin Receptor)IBA 09/2014
1	Becaplermin (PDGF-BB)FDA Link 08/2012
1	CollagenIBA 08/2012
1	Epinephrine (Adrenaline)FDA LinkGeneric 01/2012
1	GadoliniumIBA 04/2011
1	Contrast MediaIBA 04/2011
1	CalciumIBA 04/2011
1	Cyclin D1IBA 07/2006

Therapy/Procedure

3	Therapeutics 02/2022 - 01/2020
2	Injections 02/2021 - 02/2018
2	Immunotherapy 02/2021 - 01/2020
1	Cell- and Tissue-Based Therapy (Cell Therapy) 02/2021
1	Aftercare (After-Treatment) 02/2021
1	Radiotherapy 08/2007
1	Myocutaneous Flap 08/2007
1	Debridement 08/2007
1	Combination Drug Therapy (Combination Chemotherapy) 07/2006